The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase II study investigating the efficacy of daratumumab in patients with stage 3B AL amyloidosis
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, outlines early results from a Phase II study evaluating the safety and efficacy of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain (AL) amyloidosis (NCT04131309). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Honoraria; Pfizer: Honoraria, Research Funding; GSK: Honoraria; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
